

Rev 1: September 2018

FSN Ref: 4-EBR_BURK_2024.12.10_FSN

FSCA Ref: 3_EBR_BURK_2024.12.10_FSCA

Date: 10/12/2024

Urgent Field Safety Notice
Device Commercial Name

For Attention of*: Identify either by name or role who needs to be aware of the hazard and/or take action. If this is multiple recipients then include full list.

Contact details of local representative (name, e-mail, telephone, address etc.)*

This could be a distributor or local branch of the manufacturer. To be added at the appropriate stage in the different local languages



Urgent Field Safety Notice (FSN)
Device Commercial Name
Risk addressed by FSN

1. Information on Affected Devices*																																
1	<p>1. Device Type(s)*</p> <p>Brief description of the device(s) in plain language, including whether supplied sterile. Consider including a photo (here or in an Annex) where this would help with identification</p> <p>Non-sterile, non-invasive Class I classified gel</p>																															
1	<p>2. Commercial name(s)</p> <p>Add as Appendix if necessary.</p> <p>AquaUltraClear, AquaUltraBasic</p>																															
1	<p>3. Unique Device Identifier(s) (UDI-DI)</p> <p>Complete when this becomes available.</p> <table border="1"> <thead> <tr> <th>Product</th> <th>Model</th> <th>UDI</th> </tr> </thead> <tbody> <tr> <td rowspan="5">AquaUltra Clear</td> <td>UC260</td> <td>5996649001278</td> </tr> <tr> <td>UC260pp</td> <td>5996649001308</td> </tr> <tr> <td>UC500</td> <td>5996649001339</td> </tr> <tr> <td>UC1000</td> <td>5996649001360</td> </tr> <tr> <td>UCK5000</td> <td>5996649001407</td> </tr> <tr> <td rowspan="5">AquaUltra Basic</td> <td>UCU5000</td> <td>5996649001438</td> </tr> <tr> <td>UB260</td> <td>5996649000790</td> </tr> <tr> <td>UB260pp</td> <td>5996649000820</td> </tr> <tr> <td>UB500</td> <td>5996649000851</td> </tr> <tr> <td>UB1000</td> <td>5996649000882</td> </tr> <tr> <td></td> <td>UBK5000</td> <td>5996649000912</td> </tr> <tr> <td></td> <td>UBU5000</td> <td>5996649000943</td> </tr> </tbody> </table>	Product	Model	UDI	AquaUltra Clear	UC260	5996649001278	UC260pp	5996649001308	UC500	5996649001339	UC1000	5996649001360	UCK5000	5996649001407	AquaUltra Basic	UCU5000	5996649001438	UB260	5996649000790	UB260pp	5996649000820	UB500	5996649000851	UB1000	5996649000882		UBK5000	5996649000912		UBU5000	5996649000943
Product	Model	UDI																														
AquaUltra Clear	UC260	5996649001278																														
	UC260pp	5996649001308																														
	UC500	5996649001339																														
	UC1000	5996649001360																														
	UCK5000	5996649001407																														
AquaUltra Basic	UCU5000	5996649001438																														
	UB260	5996649000790																														
	UB260pp	5996649000820																														
	UB500	5996649000851																														
	UB1000	5996649000882																														
	UBK5000	5996649000912																														
	UBU5000	5996649000943																														
1	<p>4. Primary clinical purpose of device(s)*</p> <p>How the device(s) is/are used in the clinical setting/intended use.</p> <p>AquaUltraClear, AquaUltraBasic, Topical skin coupling gel for use in non sterile, non-invasive ultrasound scanning procedures.</p>																															
1	<p>5. Device Model/Catalogue/part number(s)*</p> <p>Add as Appendix if necessary.</p> <p>UB260pp, UB260, UB500, UB1000, UBU5000, UBK5000, UC260pp, UC260, UC500, UC1000, UCK5000, UCU5000</p>																															
1	<p>6. Software version</p> <p>Only where relevant.</p>																															
1	<p>7. Affected serial or lot number range</p> <p>Where relevant. If not known, use manufacturing/distribution/expiration date as appropriate. Add as Appendix if necessary or provide web-based look-up tool.</p> <p>From LOT 2024-04 to LOT 2024-10.</p>																															

1	8. Associated devices
	Within context of the FSCA eg for IVD reagents and platforms.

2 Reason for Field Safety Corrective Action (FSCA)*	
2	<p>1. Description of the product problem*</p> <p>Where there is one. Maybe "none" if eg Field Safety Notice (FSN) is to reinforce instructions for use.</p> <p>There is a potential risk of microbial contamination (<i>Burkholderia stabilis</i>) in the affected LOT of ultrasound gel. This potential link with ultrasound gel was identified during an investigation by public health authorities and the investigation is ongoing. The affected LOT was distributed within the UK and other countries during May to August 2024.</p>
2	<p>2. Hazard giving rise to the FSCA*</p> <p>Details of the greatest hazard to the patient/end user that the advice/action is intended to mitigate. Make clear whether risk is to user, patient or both. Should also try to indicate the residual risk if the FSN advice/action is taken.</p> <p>There is a potential risk of developing infection caused by <i>Burkholderia stabilis</i> if the affected ultrasound gel is used. The risk is higher in patients with cystic fibrosis, severe lung disease, severe immunocompromised and intensive care patient.</p> <p>We have identified a new hazard: the use of non-sterile, non-invasive gels in an invasive manner, as a substitute for sterile products.</p>
2	<p>3. Probability of problem arising</p> <p>Provide an indication (from incident data or prospective modelling) of the likelihood the problem will arise.</p> <p>Following stricter manufacturing technology and disinfection measures, the likelihood of occurrence is minimal. We have commissioned an accredited laboratory to prepare the validation plan and the related verification plan to improve the working environment and product cleanliness.</p>
2	<p>4. Predicted risk to patient/users</p> <p>From the output of the Health Hazard Evaluation indicate the anticipated risk (product of severity x probability) of patient/end user harm (direct or indirect).</p> <p>It poses a risk to the aforementioned patient groups. We have identified a new hazard: the use of non-sterile, non-invasive gels in an invasive manner, as a substitute for sterile products.</p>
2	<p>5. Further information to help characterise the problem</p> <p>Include any further relevant statistics to help convey the seriousness of the issue.</p> <p>Processing of accredited laboratory results. Monitoring the publication by national authorities.</p>
2	<p>6. Background on Issue</p> <p>Eg how the manufacturer became aware; brief details of relevant incidents; root cause if known; rationale for containment of problem to only affected devices; other risk mitigation or longer-term preventative action etc.</p> <p>Root cause:</p> <ul style="list-style-type: none"> - The employees did not comply with the regulations

	<ul style="list-style-type: none"> - In some cases, cleaning and disinfection were performed with tap water instead of purified water as per the requirements. - The effectiveness of the stabilizer against the Burkholderia bacteria. <p>Long term action: We have commissioned an accredited laboratory to prepare the validation plan and the related verification plan to improve the working environment and product safety. Update of Technical File and QMS documentation. Procurement of manufacturing equipment, searching for alternative disinfectants.</p>
2	<p>7. Other information relevant to FSCA</p> <p>This field may only contain additional information that is deemed necessary by the manufacturer to supplement information relevant to the FSCA.</p> <p>Supplementation of the Instructions for Use (update: risk groups and usage warnings). The label will also be updated.</p>

3. Type of Action to mitigate the risk*			
3.	<p>1. Action To Be Taken by the User*</p> <p> <input type="checkbox"/> Identify Device <input checked="" type="checkbox"/> Quarantine Device <input type="checkbox"/> Return Device <input type="checkbox"/> Destroy Device </p> <p> <input type="checkbox"/> On-site device modification/inspection </p> <p> <input type="checkbox"/> Follow patient management recommendations </p> <p> <input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU) </p> <p> <input type="checkbox"/> Other <input type="checkbox"/> None </p> <p>Provide further details of the action(s) identified.</p>		
3.	<table border="1" style="width: 100%;"> <tr> <td style="width: 35%;">2. By when should the action be completed?</td> <td>Specify where critical to patient/end user safety Immediate quarantine placement, removal by 15th of February, 2025 (The manufacturer undertakes the transportation)</td> </tr> </table>	2. By when should the action be completed?	Specify where critical to patient/end user safety Immediate quarantine placement, removal by 15th of February, 2025 (The manufacturer undertakes the transportation)
2. By when should the action be completed?	Specify where critical to patient/end user safety Immediate quarantine placement, removal by 15th of February, 2025 (The manufacturer undertakes the transportation)		
3.	<p>3. Particular considerations for: Choose an item.</p> <p>Is follow-up of patients or review of patients' previous results recommended? Choose an item.</p> <p>Provide further details of patient-level follow-up if required or a justification why none is required</p>		
3.	<table border="1" style="width: 100%;"> <tr> <td style="width: 65%;">4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)</td> <td>Yes E-mail communication</td> </tr> </table>	4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes E-mail communication
4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes E-mail communication		

3.	5. Action Being Taken by the Manufacturer	
	<input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> Software upgrade <input type="checkbox"/> Other	<input checked="" type="checkbox"/> On-site device modification/inspection <input checked="" type="checkbox"/> IFU or labelling change <input type="checkbox"/> None
	Provide further details of the action(s) identified.	
3	6. By when should the action be completed?	90 days
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?	
	Choose an item.	Choose an item.



4. General Information*	
4.	1. FSN Type* Update – 4
4.	2. For updated FSN, reference number and date of previous FSN FSN date: 15-NOV-2024 Updated FSN date: 10-DEC_2024
4.	3. For Updated FSN, key new information as follows: Summarise any key difference in devices affected and/or action to be taken. We have extended the recall activity to cover the product AquaUltra Clear and AquaUltra Basic.
4.	4. Further advice or information already expected in follow-up FSN? * Following the preparation of the validation and verification protocols, the technical documentation and ISO documentation will be updated based on the new measurement results.
4	5. If follow-up FSN expected, what is the further advice expected to relate to: Eg patient management, device modifications etc
4	6. Anticipated timescale for follow-up FSN For provision of updated advice. By 31st December, 2024.
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)
	a. Company Name Ultrigel Medical Kft
	b. Address 1022 Budapest, Aranka utca 12.
	c. Website address Only necessary if not evident on letter-head.
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. * NNGYK - Nemzeti Népegészségügyi Központ / National Public Health Center
4.	9. List of attachments/appendices: Annex 1: list of authorities; Annex 2. list of distributors; Annex 3. List of Hungarian distributors
4.	10. Name/Signature Insert Name and Title here and signature below

Transmission of this Field Safety Notice	
	This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)
	Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

<p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback..*</p>
--

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.


Ultrageł Medical Kft.
Sz.h.: 1022 Budapest, Aranka u. 12.
Adószám: 27751015-2-41

1000

6